公开(公告)号：PL194175B1

公开(公告)日：2007-05-31

申请号：PL35541898

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：NZ521734A

公开(公告)日：2004-10-29

申请号：NZ52173401

申请日：2001-04-27

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  TIETJE KARIN R ,  TOUPENCE RICHARD B ,  JI JIANGUO ,  BASHA ANWER ,  BUNNELLE WILLIAM H ,  DAANEN JEROME F ,  PACE JENNIFER M ,  SIPPY KEVIN B

IPC: C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D471/08 ,  C07D519/00 ,  A61K31/395

Abstract: Disclosed herein are N-substituted diazabicyclic compounds of formula (I) and pharmaceutical compositions thereof that are suitable for controlling synaptic transmission in mammals (nicotinic acetylcholine receptor ligands), wherein A, B, R1, R9, Y and Z are as defined in the specification. A method for selectively controlling neurotransmitter release in mammals using these compounds for controlling pain in mammals is also described.

公开(公告)号：NO315423B1

公开(公告)日：2003-09-01

申请号：NO20000863

申请日：2000-02-22

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：MXPA02010594A

公开(公告)日：2003-05-14

申请号：MXPA02010594

申请日：2001-04-27

Applicant: ABBOTT LAB

Inventor： BASHA ANWER

IPC: C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/04

Abstract: Los compuestos de la Formula (I), composiciones farmaceuticas de estos compuestos, y el uso de dichas composiciones para controlar la transmision sinaptica en mamiferos (ligantes de receptor de acetilcolina nicotinica).

公开(公告)号：CZ20023765A3

公开(公告)日：2003-02-12

申请号：CZ20023765

申请日：2001-04-27

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BUNNELLE WILLIAM H ,  DAANEN JEROME F ,  PACE JENNIFER M ,  SIPPY KEVIN B ,  SCHRIMPF MICHAEL R ,  TIETJE KARIN R ,  TOUPENCE RICHARD B ,  JI JIANGUO

IPC: C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D471/08 ,  A61K31/395

Abstract: Compounds of formula (I), pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals

公开(公告)号：PL349256A1

公开(公告)日：2002-07-01

申请号：PL34925699

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：TR200000478T2

公开(公告)日：2002-04-22

申请号：TR200000478

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：PE13052001A1

公开(公告)日：2001-12-31

申请号：PE0003852001

申请日：2001-04-27

Applicant: ABBOTT LAB

Inventor： TOUPENCE RICHARD B ,  BASHA ANWER ,  BUNNELLE WILLIAM H ,  DAANEN JEROME F ,  TIETJE KARIN R ,  PACE JENNIFER MARY ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  JI JIANGUO

IPC: C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/00 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: SE REFIERE A AGENTES DIAZABICICLICOS DE FORMULA I DONDE A ES UN ENLACE, CH2, (CH2)2, (CH2)3; B ES CH2, (CH2)2; SI A ES (CH2)3, B ES CH2; Y ES ENLACE, CH2, (CH2)2; Z ES ENLACE, CH2, (CH2)2, SI Y ES (CH2)2; Z ES ENLACE SI Z ES (CH2)2 Y ES ENLACE; R1 ES UN GRUPO a, b, c; R3 ES H, ALQUILO, HALOGENO; R4 ES H, ALCOXILO, ALQUILO, ENTRE OTROS; R5 ES H, ALQUENILO, ALCOXILO, ENTRE OTROS; R6, R7 R8 SON H, ALQUILO; R9 ES H, ALCOXICARBONILO, ALQUILO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (CIS)-6-(3-PIRIDINIL)-3,6-DIAZABICICLO[3.2.0]HEPTANO, (CIS)-8-(3-PIRIDINIL)-3,8-DIAZABICICLO[4.2.0]OCTANO, (CIS)-1-(6-CLORO-3-PIRIDINIL)OCTAHIDROPIRROLO[3,4-b]PIRROL. EL COMPUESTO I O EN COMBINACION CON ANTIINFLAMATORIO NO ESTEROIDEO, OPIOIDE, ANTIDEPRESIVO TRICICLICO, ANTICONVULSIVANTE PUEDE SER UTIL PARA CONTROLAR LA LIBERACION DE UN NEUROTRASMISOR COMO ALZHEIMER, MAL DE PARKINSON, TRASTORNO DE HIPERACTIVIDAD CON DEFICIT DE ATENCION, DEPRESION, SINDROME DE ABANDONO DE NICOTINA, SINDROME DE TOURETTE, ESQUIZOFRENIA

公开(公告)号：CA2407094A1

公开(公告)日：2001-11-01

申请号：CA2407094

申请日：2001-04-27

Applicant: ABBOTT LAB

Inventor： TIETJE KARIN R ,  SCHRIMPF MICHAEL R ,  TOUPENCE RICHARD B ,  BASHA ANWER ,  BUNNELLE WILLIAM H ,  JI JIANGUO ,  DAANEN JEROME F ,  SIPPY KEVIN B ,  PACE JENNIFER M

IPC: C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D209/00 ,  C07D221/00 ,  C07D241/00 ,  C07D519/00 ,  C07D471/08 ,  A61K31/395

Abstract: Compounds of formula (I), pharmaceutical compositions of these compounds, an d use of said compositions to control synaptic transmission in mammals (nicotinic acetylcholine receptor ligands).

公开(公告)号：NO20012061L

公开(公告)日：2001-06-27

申请号：NO20012061

申请日：2001-04-26

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).